ストックスクリーナーアプリを入手
2.57
0.39%
0.010
アフターアワーズ：
2.62
0.05
+1.95%
Kalaris Therapeutics Inc (KLRS) 最新ニュース
Kalaris Therapeutics, Inc.Common Stock (Nasdaq:KLRS) Stock Quote - FinancialContent
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference - The Manila Times
Kalaris Therapeutics CEO Reveals Latest Retinal Disease Progress at Noble Capital Conference - Stock Titan
Kalaris: Phase 1 Trial for TH103 Advances Following AlloVir Merger and Other Important Updates - TradingView
Kalaris to Participate at Stifel Ophthalmology Forum - The Manila Times
Kalaris Leadership Team to Reveal Latest Ophthalmology Strategy at Prestigious Stifel Forum - Stock Titan
Pre-market Movers: IXHL, KLRS, HCTI, DOCS... - RTTNews
Kalaris Therapeutics Reports Q1 2025 Financials and Progress - TipRanks
Kalaris Therapeutics, Inc. SEC 10-Q Report - TradingView
Kalaris Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Kalaris Therapeutics reports Q1 EPS ($2.52) vs ($2.60) last year - TipRanks
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights - The Manila Times
Kalaris Eyes Breakthrough in AMD Treatment: Phase 1 Trial Progress and $101M War Chest Revealed in Q1 Earnings - Stock Titan
Kalaris Therapeutics restructures executive compensation By Investing.com - Investing.com South Africa
Kalaris Therapeutics restructures executive compensation - Investing.com
Kalaris Therapeutics Amends Executive Employment Agreements - TipRanks
Kalaris Therapeutics initiated with an Outperform at William Blair - MSN
AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-The-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses - MarketScreener
William Blair initiates Kalaris stock with Outperform rating By Investing.com - Investing.com UK
William Blair Initiates Kalaris Therapeutics With Outperform Rating - marketscreener.com
Kalaris Therapeutics appoints new board chair By Investing.com - Investing.com Canada
The Gross Law Firm Notifies Shareholders of AlloVir, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2024(NASDAQ: ALVR) - MarketScreener
Kalaris Therapeutics appoints new board member - Investing.com Australia
Kalaris Therapeutics Appoints Leone Patterson to Board - TipRanks
Kalaris Therapeutics appoints new board member By Investing.com - Investing.com Canada
Kalaris Therapeutics appoints new board chair - Investing.com Australia
Kalaris Expands Board Of Directors Appointing Leone Patterson As Chair Of Audit Committee - marketscreener.com
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee - TradingView
Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and Innovation - 01net
ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - MarketScreener
ALVR Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - MarketScreener
KLRS stock touches 52-week low at $7.75 amid market challenges - Investing.com
The Law Offices of Vincent Wong Remind AlloVir Investors of a Lead Plaintiff Deadline of March 19, 2024 - MarketScreener
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionALVR - MarketScreener
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact Levi & Korsinsky - MarketScreener
ALLOVIR SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - Marketscreener.com
Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) Investors of a Class Action Lawsuit and Upcoming Deadline - MarketScreener
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 - Investing.com India
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 By Investing.com - Investing.com UK
Kalaris and AlloVir Inc. complete merger - Ophthalmology Times
Kalaris Therapeutics Announces Closing of Merger With AlloVir - VisionMonday.com
Kalaris Therapeutics Inc. (KLRS) - Zacks Investment Research
ALLOVIR, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts against AlloVir, Inc. - Marketscreener.com
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
Kalaris Therapeutics Completes Merger with AlloVir -March 19, 2025 at 04:18 am EDT - Marketscreener.com
AlloVir Merges with Kalaris Therapeutics, Inc. - TipRanks
Kalaris Therapeutics Completes Merger with AlloVir, Advances Phase 1 Trial of TH103 for Neovascular Retina Diseases - Nasdaq
Kalaris Secures $100M War Chest for Revolutionary Macular Degeneration Treatment - StockTitan
Shootin' the Bull about cattle feeders - The Globe and Mail
2.13%
1.01%
大文字化:
|
ボリューム (24 時間):